STOCK TITAN

Curis expects cash to fund operations into Q1 2027

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Curis, Inc. reported a third-quarter 2026 net loss of $8.120 million, compared with $7.729 million a year earlier, and a nine-month net loss of $40.900 million versus $26.938 million. It reported no revenue in the 2026 periods, following the 2025 sale of Erivedge royalties; revenue was $3.176 million for Q3 2025 and $8.305 million for the first nine months of 2025.

Curis said it is enrolling patients in two emavusertib combination studies. PCNSL data as of July 1, 2026 showed response rates of 26% (10 of 39) among all BTKi-experienced patients and 86% (6 of 7) among all BTK-naïve patients; among evaluable patients, rates were 33% (10 of 30) and 100% (5 of 5), respectively. The CLL study had enrolled 12 patients, with initial data expected in December 2026.

Cash and cash equivalents were $5.014 million as of September 30, 2026. Curis said cash plus approximately $7.5 million in net proceeds from its October 2026 private placement should fund existing operations into Q1 2027, while also stating that available cash was insufficient to support current operations within the next 12 months. It said substantial additional funding is required to develop emavusertib and support operations.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

2 major · 4 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • None.

Negative

  • Major pointNine-month net loss reached $40.900 million, versus $26.938 million in 2025.
  • Major point. Forward-looking: it has not happened yet and may not happen.Available cash was insufficient for current operations within the next 12 months.
  • Moderate pointNo revenue was reported in Q3 2026, versus $3.176 million in Q3 2025.
  • Minor pointQuarterly net loss reached $8.120 million, versus $7.729 million in 2025.
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Third-quarter net loss $8.120 million Three months ended September 30, 2026; compared with $7.729 million in 2025.
Nine-month net loss $40.900 million Nine months ended September 30, 2026; compared with $26.938 million in 2025.
Revenue No revenue reported Three months ended September 30, 2026; revenue was $3.176 million in the 2025 period.
Cash and cash equivalents $5.014 million As of September 30, 2026.
Net private-placement proceeds Approximately $7.5 million October 2026 private placement.
Patients enrolled 12 patients TakeAim CLL study; reported November 12, 2026.
PCNSL ORR, BTKi-experienced patients 26% (10 of 39 patients) All patients; data as of July 1, 2026.
PCNSL ORR, BTK-naïve patients 86% (6 of 7 patients) All patients; data as of July 1, 2026.
IRAK4 and FLT3 inhibitor medical
"small molecule IRAK4 and FLT3 inhibitor"
open label phase 2 study medical
"is an open label phase 2 study"
registrational study regulatory
"is a registrational study"
A registrational study is a late-stage clinical trial designed to give the government regulators the evidence they need to decide whether a drug, therapy, or medical device can be approved for sale. Think of it as the final exam or road test for a medical product: its results largely determine whether the product can reach the market, which directly affects potential revenue, company valuation, and investor risk.
measurable residual disease (MRD+) medical
"measurable residual disease (MRD+)"
accelerated approval regulatory
"support regulatory applications for accelerated approval"
Accelerated approval is a process that allows new medical treatments to be approved more quickly than usual if they address serious or life-threatening conditions and show promising early results. For investors, it signals that a treatment may reach the market sooner, potentially boosting a company's prospects, but it also involves some uncertainty since full evidence of effectiveness is still being gathered.
Orphan Drug Designation regulatory
"has received Orphan Drug Designation"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
Revenue, net No revenue reported Compared with $3.176 million in the three months ended September 30, 2025.
Net loss $8.120 million Compared with $7.729 million in the three months ended September 30, 2025.
Research and development expenses $5.595 million Compared with $6.432 million in the three months ended September 30, 2025.
General and administrative expenses $3.153 million Compared with $3.653 million in the three months ended September 30, 2025.
Net loss per common share, basic and diluted $(1.94) Compared with $(9.86) in the three months ended September 30, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were CRIS's third-quarter 2026 results?

Curis reported a net loss of $8.120 million for the three months ended September 30, 2026, compared with $7.729 million a year earlier. It reported no revenue for the quarter, versus $3.176 million in the same 2025 period.

How long does CRIS expect its cash to last?

Curis said its $5.014 million in cash and cash equivalents as of September 30, 2026, together with approximately $7.5 million in net October private-placement proceeds, should fund existing operations into Q1 2027. The company also said available cash was insufficient to support current operations within the next 12 months.

What response rates did CRIS report in its PCNSL study?

As of July 1, 2026, the all-patient objective response rate was 26% (10 of 39) for BTKi-experienced patients and 86% (6 of 7) for BTK-naïve patients. Among evaluable patients, the respective rates were 33% (10 of 30) and 100% (5 of 5).

How many patients are enrolled in CRIS's CLL study, and when is initial data expected?

Curis reported that 12 patients had been enrolled in the TakeAim CLL study, with initial data expected in December 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001108205 0001108205 2026-11-12 2026-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event Reported): November 12, 2026

 

Curis, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware000-3034704-3505116
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification Number)

 

128 Spring Street, Building C - Suite 500, Lexington MA 02421

(Address of Principal Executive Offices) (Zip Code)

 

(617) 503-6500

(Registrant's telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, Par Value $0.01 per share   CRIS   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On November 12, 2026, Curis, Inc. announced its financial results for the three-month periods ended September 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

 

 

 

Item 9.01. Financial Statements and Exhibits.

 

Exhibit Number Description
   
99.1 Press Release dated November 12, 2026
104 Cover Page Interactive Data File (embedded within the InLine XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Curis, Inc.
     
     
Date: November 13, 2026 By: /s/ Diantha Duvall
      Diantha Duvall
      Chief Financial Officer

 

 

 

 

Exhibit 99.1

 

 

 

PRESS RELEASE

 

Curis Provides Third Quarter 2026 Business Update

 

Management to host conference call and webcast today at 4:30 p.m. ET

 

LEXINGTON, Mass., November 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its financial and operating results for the third quarter ended September 30, 2026.

 

“We are encouraged by our progress in both the TakeAim CLL study and the TakeAim Lymphoma study,” said James Dentzer, Chief Executive Officer of Curis. “The excitement among clinicians and patients reflects the clear unmet need in both CLL and PCNSL, where emavusertib has the potential to change the treatment landscape when combined with approved BTK inhibitors.”

 

Operational Highlights

 

Curis is currently enrolling patients in 2 ongoing studies, the TakeAim CLL study (CA-4948-203, NCT07271667) and the TakeAim Lymphoma study in PCNSL (CA-4948-101, NCT03328078).

 

TakeAim CLL

 

The TakeAim CLL Study is an open label phase 2 study of emavusertib in combination with zanubrutinib in patients with CLL. To be eligible for enrollment, participants must have received zanubrutinib for at least 12 months, achieved a partial response (PR) or partial response with lymphocytosis (PR-L), and have measurable residual disease (MRD+) as determined by the clonoSEQ assay.

 

To date, 12 patients have been enrolled in the study with initial data expected in December 2026.

 

TakeAim Lymphoma

 

The TakeAim Lymphoma Study is a registrational study of emavusertib in combination with ibrutinib in patients with Relapsed/Refractory (R/R) PCNSL (CA-4948-101, NCT03328078). In 2025, Curis presented initial clinical data to the U.S. Food and Drug Administration (FDA) and European Medicines Agency’s Committee for Medicinal Products for Human Use (EMA) and received guidance that the ongoing registrational study could support regulatory applications for accelerated approval in R/R PCNSL.

 

 

 

 

In July 2026, the Company reported updated data for 7 BTK-naïve and 39 BTKi-experienced patients:

 

  (as of July 1, 2026)
     
  Evaluable* All
  Patients Patients
     
BTKi-naïve 100% ORR 86% ORR
(5 of 5) (6 of 7)
     
BTKi-experienced 33% ORR
(10 of 30)
26% ORR
(10 of 39)

 

* evaluable excludes patients who did not complete at least 1 cycle (~1 month) of treatment

 

About PCNSL and CLL

 

In PCNSL and CLL, disease is driven by NF-kB dysregulation, which is in turn driven by two biologic pathways: BCR and TLR1. The goal of combining emavusertib with a BTK inhibitor (BTKi) in the TakeAim Lymphoma and TakeAim CLL Studies is to enable a dual blockade of NF-kB, by inhibiting both the BCR and TLR pathways. BTKi blocks the BCR pathway; emavusertib blocks the TLR pathway.

 

BTKi is an established standard of care in Relapsed/Refractory (R/R) PCNSL. For BTKi-naïve patients, response rates can be 39%-67%. For salvage-line patients, patients who have been treated with BTKi and progressed, outcomes are generally poor, with many patients proceeding directly to hospice or best supportive care. Initial clinical data have shown that adding emavusertib to a BTKi regimen, directly after a patient progresses on BTKi monotherapy, can enable patients to reverse their disease progression and achieve an objective response.

 

BTKi is also standard of care in CLL, where outcomes are more favorable than in PCNSL. In the registrational study for the BTKi zanubrutinib in CLL, 93% of patients were able to achieve an objective response, though only 7% achieved complete response2. More recent clinical studies have shown that adding emavusertib to a BTKi regimen, blocking both the TLR and BCR pathways, can enable patients with NHL to achieve deeper responses, including complete responses or undetectable minimal residual disease (MRD).

 

Corporate

 

Completed a public offering in August 2026 and a private placement in October 2026 extending cash runway into 2027.

 

 

1 Bennett, Curr Opin Hematol. 2022

 

2 Zanubrutinib USPI

 

 

 

 

Third Quarter 2026 Financial Results

 

For the third quarter of 2026, Curis reported a net loss of $8.1 million or $1.94 per share on both a basic and diluted basis as compared to $7.7 million or $9.86 per share on both a basic and diluted basis, for the same period in 2025. Curis reported a net loss of $40.9 million or $16.77 per share on both a basic and diluted basis, for the nine months ended September 30, 2026, as compared to a net loss of $26.9 million or $43.82 per share on both a basic and diluted basis for the same period in 2025.

 

There was no revenue reported for the quarter or the year ended September 30, 2026 due to the sale of Erivedge® royalties to Oberland in the fourth quarter of 2025. Revenues were $3.2 million and $8.3 million for the quarter and year ended September 30, 2025, respectively.

 

Research and development expenses were $5.6 million for the third quarter of 2026, as compared to $6.4 million for the same period in 2025. The decrease was primarily attributable to lower employee-related costs, partially offset by an increase in clinical costs. Research and development expenses were $18.8 million for the nine months ended September 30, 2026, as compared to $22.4 million for the same period in 2025.

 

General and administrative expenses were $3.2 million for the third quarter of 2026, as compared to $3.7 million for the same period in 2025. The decrease was primarily attributable to lower employee-related costs, partially offset by an increase in legal costs. General and administrative expenses were $11.4 million for the nine months ended September 30, 2026, as compared to $11.2 million for the same period in 2025.

 

Other income was $0.6 million for the third quarter of 2026, as compared to other expense of $0.8 million for the same period in 2025. The increase was primarily attributable to the change in fair value of the warrant liability associated with the January 2026 Private Placement, partially offset by a decrease in the expense related to the sale of future royalties. Other expense was $10.7 million for the nine months ended September 30, 2026, as compared to other expense of $1.6 million for the same period in 2025.

 

Curis's cash and cash equivalents totaled $5.0 million as of September 30, 2026, and the Company had approximately 4.1 million shares of common stock outstanding. The Company believes that the $5.0 million of existing cash and cash equivalents as of September 30, 2026, together with the net proceeds of approximately $7.5 million from the October 2026 Private Placement, should enable it to fund our existing operations into the first quarter of 2027.

 

Conference Call and Webcast Information

 

Curis management will host a conference call today, November 12, 2026, at 4:30 p.m. ET, to discuss the business update and these financial results.

 

Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast can be accessed here or from the investor section of the Curis website. A replay of the conference call will be available at www.curis.com.

 

About Curis, Inc.

 

Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 and FLT3 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) of emavusertib in combination with the BTK inhibitor, ibrutinib, in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and in the TakeAim CLL Phase 2 study (CA-4948-203) of emavusertib in combination with the BTK inhibitor, zanubrutinib, in chronic lymphocytic leukemia (CLL). The Company's monotherapy and combination studies in acute myeloid leukemia (AML) are substantially complete, with additional funding the Company plans to continue development of emavusertib in AML. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. Curis, through its 2015 collaboration with Aurigene Discovery Technologies Limited, has the exclusive license to emavusertib (CA-4948). For more information, visit Curis's website at www.curis.com.

 

 

 

 

Cautionary Note Regarding Forward-Looking Statements:

 

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning Curis's cash runway, the therapeutic potential of emavusertib in combination with zanubrutinib to improve treatment outcomes, achieve complete remissions and/or undetectable MRD, and/or reduce time on treatment for patients with CLL; Curis's expectations with respect to enrollment of BTKi naïve and BTKi experienced populations in the TakeAim Lymphoma study; the use of such data to support regulatory filings for approval of emavusertib in PCNSL, and the therapeutic potential and tolerability of emavusertib in patients with PCNSL. Forward-looking statements may contain the words "believes," "expects," "anticipates," "plans," "intends," "seeks," "estimates," "assumes," "predicts," "projects," "targets," "will," "may," "would," "could," "should," "likelihood", "continue," "potential," "opportunity," "focus," "strategy," "mission," or similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other important factors that may cause actual results to be materially different from those indicated by such forward-looking statements. Curis may experience adverse results, delays and/or failures in its drug development programs and may not be able to successfully advance the development of its drug candidates in the time frames it projects, if at all. Curis's drug candidates may cause unexpected toxicities, fail to demonstrate sufficient safety and efficacy in clinical studies and/or may never achieve the requisite regulatory approvals needed for commercialization. Favorable results seen in preclinical studies and early clinical trials of Curis's drug candidates may not be replicated in later trials. Curis is dependent on the success of emavusertib and any delays in the development of emavusertib could have a material adverse effect on its business. There can be no guarantee that the collaboration agreement with Aurigene or the CRADA with NCI will continue for their full terms, that Curis or its collaborators will each maintain the financial and other resources necessary to continue financing its portion of the research, development and commercialization costs, or that the parties will successfully discover, develop or commercialize drug candidates under the collaboration. Curis will require substantial additional capital to fund its business. Based on its available cash resources, it does not have sufficient cash on hand to support current operations within the next 12 months from the date of this press release. Curis will require substantial additional funding to fund the development of emavusertib through regulatory approval and commercialization, and to support its continued operations. If it is not able to obtain sufficient funding, it will be forced to delay, reduce in scope or eliminate the development of emavusertib, including related clinical trials and operating expenses, potentially delaying the time to market for, or preventing the marketing of, emavusertib, which could adversely affect its business prospects and its ability to continue operations, and would have a negative impact on its financial condition and its ability to pursue its business strategies. Curis faces substantial competition. Curis and its collaborators face the risk of potential adverse decisions made by the FDA, EMA and other regulatory authorities, investigational review boards, and publication review bodies. Curis may not obtain or maintain necessary patent protection and could become involved in expensive and time-consuming patent litigation and interference proceedings. Unstable market and economic conditions, natural disasters, public health crises, political crises and other events outside of Curis's control, including its ability to regain and maintain its listing on the Nasdaq Capital Market, could significantly disrupt its operations or the operations of third parties on which Curis depends and could adversely impact Curis's operating results and its ability to raise capital. Other important factors that may cause or contribute to actual results being materially different from those indicated by forward-looking statements include the factors set forth under the captions "Risk Factor Summary" and "Risk Factors" in our most recent Form 10-K, and the factors that are discussed in other filings that Curis periodically makes with the Securities and Exchange Commission. In addition, any forward-looking statements represent the views of Curis only as of today and should not be relied upon as representing Curis's views as of any subsequent date. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by law.

 

For further information:

 

Investor Relations: IR@curis.com

 

 

 

 

CURIS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

 

(UNAUDITED)

(In thousands, except share and per share data)

 

  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
   2026   2025   2026   2025 
Revenues, net  $—   $3,176   $—   $8,305 
Operating expenses:                    
Cost of royalties   —    15    —    45 
Research and development   5,595    6,432    18,758    22,429 
General and administrative   3,153    3,653    11,449    11,163 
Total operating expenses   8,748    10,100    30,207    33,637 
Loss from operations   (8,748)   (6,924)   (30,207)   (25,332)
Total other income (expense)   628    (805)   (10,693)   (1,606)
Net loss  $(8,120)  $(7,729)  $(40,900)  $(26,938)
Net loss per common share (basic and diluted)  $(1.94)  $(9.86)  $(16.77)  $(43.82)
Weighted average common shares (basic and diluted)   4,178,648    784,109    2,439,370    614,771 

 

 

 

 

CURIS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

(UNAUDITED)

(In thousands)

 

   September 30, 2026   December 31, 2025 
ASSETS          
Cash and cash equivalents  $5,014   $5,061 
Restricted cash   544    544 
Prepaid expenses and other assets   3,370    3,427 
Property and equipment, net   36    62 
Operating lease right-of-use asset   853    1,890 
Goodwill   8,982    8,982 
Total assets  $18,799   $19,966 
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Accounts payable and accrued liabilities  $15,508   $12,886 
Operating lease liability   740    1,618 
Total liabilities   16,248    14,504 
Total stockholders' equity (deficit)   2,551    5,462 
Total liabilities and stockholders' equity (deficit)  $18,799   $19,966 

 

 

 

Filing Exhibits & Attachments

4 documents

Keep reading